Xgeva gains NICE recommendation for bone metastasis
05:06 EDT 17 Aug 2012 | InPharm
NICE is continuing to recommend Amgen’s Xgeva for certain groups of cancer patients whose disease has spread to their bones. In final draft guidance the watchdog recommends Xgeva (denosumab) as a treatment for people with bone metastases from most..
Original Article: Xgeva gains NICE recommendation for bone metastasis
More From BioPortfolio on "Xgeva gains NICE recommendation for bone metastasis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
